Drug Type Small molecule drug |
Synonyms Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid, Ethambutol Hydrochloride/Pyrazinamide/Rifampicin/Isoniazid, Ethylpyrazine rifampicide + [3] |
Target |
Mechanism RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date DK (06 Mar 2003), |
Regulation- |
Molecular FormulaC5H5N3O |
InChIKeyIPEHBUMCGVEMRF-UHFFFAOYSA-N |
CAS Registry98-96-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ethambutol Hydrochloride/Isoniazid/Pyrazinamide/Rifampicin | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pulmonary Tuberculosis | DK | 06 Mar 2003 |
Phase 4 | 851 | (Arm A: Empiric) | zgyxszkgcp(dhzmvyohsz) = iaxfbfymee awftgiukoh (qwekrvycxb, iyyhbnyyhi - ssgwcqysct) View more | - | 23 Feb 2016 | ||
(Arm B: IPT) | zgyxszkgcp(dhzmvyohsz) = wvsmcagrxg awftgiukoh (qwekrvycxb, dzwgmunagm - dthevuqwad) View more | ||||||
Phase 1 | - | 36 | Myrin-P Forte (Myrin-P Forte) | ynxcuocrxz(jizameshhw): Ratio of Adjusted Means = 103.81 (90% CI, 99.20 - 108.64); Ratio of Adjusted Means = 107.28 (90% CI, 101.95 - 112.90); Ratio of Adjusted Means = 99.48 (90% CI, 94.92 - 104.25) View more | - | 16 Mar 2012 | |
ethambutol+rifampicin+isoniazid+pyrazinamide (Four Single Drug References) |